Matrifen: Uses, Dosage & Side Effects
A transdermal fentanyl patch delivering continuous opioid analgesia for the management of chronic severe pain in opioid-tolerant patients
Matrifen is a prescription transdermal patch containing fentanyl, a potent synthetic opioid analgesic approximately 80–100 times more potent than morphine. It is indicated for the management of chronic severe pain that requires continuous, around-the-clock opioid treatment in patients who are already opioid-tolerant. Matrifen delivers fentanyl through the skin into the bloodstream at a controlled rate over 72 hours (3 days), providing stable pain relief without the fluctuations associated with oral opioid dosing. This medication is commonly prescribed for cancer pain and severe chronic non-cancer pain when other analgesics are inadequate. Due to the risk of fatal respiratory depression, Matrifen must never be used in opioid-naive patients, for acute pain, or for intermittent pain management.
Quick Facts: Matrifen
Key Takeaways
- Matrifen is a transdermal fentanyl patch used exclusively for chronic severe pain in patients already tolerant to opioid therapy — it must never be used in opioid-naive patients due to the risk of fatal respiratory depression.
- Each patch is applied to clean, dry, non-hairy skin on the upper body or thigh and delivers continuous pain relief for 72 hours (3 days) before needing replacement.
- Available in five strengths (12, 25, 50, 75, and 100 mcg/h), allowing individualized dosing based on the patient’s prior opioid requirements and response to treatment.
- External heat sources (heating pads, saunas, hot baths, fever) can dramatically increase fentanyl absorption and must be avoided, as this can lead to fatal overdose.
- Used patches still contain significant residual fentanyl and must be disposed of safely by folding adhesive sides together and returning to a pharmacy — accidental exposure to children or pets can be fatal.
What Is Matrifen and What Is It Used For?
Matrifen belongs to a class of medicines known as strong opioid analgesics. Its active substance, fentanyl, is a synthetic phenylpiperidine opioid agonist that was first synthesized by Paul Janssen in 1960 and has since become one of the most widely used opioids in clinical practice worldwide. Fentanyl is classified as a Schedule II controlled substance in the United States and a Schedule 2 drug in the United Kingdom, reflecting its high therapeutic value but also its significant potential for misuse and dependence. The transdermal formulation (skin patch) was developed to provide a non-invasive method of delivering continuous opioid analgesia, offering a practical alternative to oral, intravenous, or intramuscular routes of administration.
The Matrifen transdermal system works by incorporating fentanyl into a specially engineered matrix patch that adheres to the skin surface. Once applied, fentanyl diffuses from the patch through the outer layers of the skin (stratum corneum and epidermis) into the dermal microcirculation, creating a subcutaneous depot of drug. From this depot, fentanyl is continuously absorbed into the systemic circulation at a controlled, predictable rate. This transdermal delivery mechanism provides several clinical advantages over oral opioid formulations. It bypasses first-pass hepatic metabolism (which significantly reduces the bioavailability of oral fentanyl), maintains relatively stable plasma concentrations over the 72-hour application period, and eliminates the peaks and troughs associated with repeated oral dosing that can cause alternating episodes of breakthrough pain and excessive sedation.
Fentanyl exerts its analgesic effects primarily by binding to mu-opioid receptors (MOR) in the central nervous system and spinal cord dorsal horn. These receptors are G-protein coupled receptors that, when activated, inhibit adenylyl cyclase, reduce calcium influx through voltage-gated calcium channels, and enhance potassium efflux through inwardly rectifying potassium channels. The net effect of this receptor activation is a profound reduction in neurotransmitter release from nociceptive (pain-sensing) neurons, suppression of ascending pain signals in the spinothalamic tract, and modulation of the emotional and affective components of pain perception in limbic and cortical brain regions. Fentanyl is approximately 80 to 100 times more potent than morphine on a weight-for-weight basis, meaning that very small quantities can produce significant analgesic effects.
Matrifen is indicated for the management of chronic severe pain that requires continuous, around-the-clock opioid administration and that cannot be adequately controlled by other means, including non-opioid analgesics, adjuvant therapies, or weaker opioids. The primary indications include:
- Cancer pain: Matrifen is widely used in oncology for patients with moderate-to-severe cancer pain who have been stabilized on other opioids. The World Health Organization (WHO) analgesic ladder recommends strong opioids such as fentanyl for Step 3 pain management when paracetamol, NSAIDs, and weak opioids (codeine, tramadol) are no longer sufficient.
- Chronic non-cancer pain: In carefully selected patients with severe chronic non-cancer pain (such as neuropathic pain, severe osteoarthritis, or chronic back pain), Matrifen may be prescribed when other treatment modalities have failed. However, international guidelines emphasize that opioids should be used for chronic non-cancer pain only after thorough assessment, with regular review, and as part of a multimodal pain management strategy.
- Palliative care: Matrifen is commonly used in palliative care settings to provide consistent pain relief for patients with advanced, life-limiting illnesses, particularly when oral medication is difficult due to nausea, vomiting, dysphagia, or impaired consciousness.
Matrifen is intended ONLY for patients who are already tolerant to opioid therapy. Opioid-tolerant patients are those who have been taking, for a week or longer, at least 60 mg of oral morphine daily, or at least 25 mcg/h of transdermal fentanyl, or an equianalgesic dose of another opioid. Using Matrifen in patients who are not opioid-tolerant can cause fatal respiratory depression. Matrifen is NOT indicated for acute pain, postoperative pain, or intermittent pain that can be managed with other analgesics.
Clinical studies and extensive post-marketing surveillance over more than two decades have established the efficacy of transdermal fentanyl in providing sustained pain relief. Randomized controlled trials have demonstrated that transdermal fentanyl provides equivalent analgesia to sustained-release oral morphine, with potential advantages in terms of constipation (a common and distressing opioid side effect) and patient preference. A Cochrane systematic review evaluating transdermal fentanyl for cancer pain concluded that it is an effective analgesic with a side effect profile that some patients may prefer over oral morphine, particularly regarding gastrointestinal tolerability.
What Should You Know Before Taking Matrifen?
Contraindications
Matrifen must not be used in the following situations, as doing so could lead to serious, potentially life-threatening consequences:
- Opioid-naive patients: The most critical contraindication. Patients who have not been taking regular opioid medications must not use Matrifen, as even the lowest-strength patch (12 mcg/h) can deliver a dose capable of causing fatal respiratory depression in non-tolerant individuals.
- Hypersensitivity: Do not use Matrifen if you are allergic to fentanyl or to any of the other ingredients in the patch, including the adhesive components.
- Severe respiratory depression: Matrifen is contraindicated in patients with severe respiratory depression, acute or severe bronchial asthma, or any condition where respiratory function is significantly compromised.
- Acute or intermittent pain: Matrifen is not suitable for short-term or intermittent pain, including postoperative pain, headache, or pain that can be managed with other analgesics. The slow onset of action (12–24 hours to reach therapeutic levels) and long duration of effect make it inappropriate for acute pain management.
- Severe hepatic impairment: Patients with severe liver disease may have impaired metabolism of fentanyl, leading to dangerously elevated plasma concentrations.
Warnings and Precautions
Serious, life-threatening, or fatal respiratory depression can occur with the use of Matrifen. This risk is greatest during initiation of therapy, following a dose increase, and when used concomitantly with other CNS depressants. Monitor patients closely, especially within the first 24–72 hours after starting or increasing the dose. Ensure that naloxone (an opioid reversal agent) is available to caregivers.
Before starting Matrifen, discuss the following with your healthcare provider:
- Heat exposure: Application of external heat to the Matrifen patch can increase fentanyl absorption by up to 120%, potentially leading to fatal overdose. Avoid heating pads, electric blankets, heated waterbeds, sunbathing, hot baths, saunas, and hot tubs while wearing the patch. Patients with fever should be monitored closely, as elevated body temperature can also increase drug absorption.
- Concomitant CNS depressants: Concurrent use of Matrifen with benzodiazepines (diazepam, lorazepam, alprazolam), other opioids, sedative antihistamines, alcohol, gabapentinoids, or general anesthetics can result in profound sedation, respiratory depression, coma, and death. If co-prescribing is unavoidable, use the lowest effective doses and shortest possible duration, with close monitoring.
- Serotonin syndrome: When used with serotonergic medications (SSRIs, SNRIs, MAO inhibitors, triptans, certain antibiotics such as linezolid), fentanyl can contribute to serotonin syndrome — a potentially life-threatening condition characterized by agitation, confusion, rapid heart rate, hyperthermia, muscle rigidity, and tremor.
- Accidental exposure: Accidental exposure to Matrifen, particularly in children, can be fatal. A used patch retains a substantial amount of fentanyl (up to 50–80% of the original dose). Patients must store patches securely, apply them carefully, and dispose of them properly.
- Adrenal insufficiency: Long-term opioid use, including fentanyl, can suppress hypothalamic-pituitary-adrenal axis function, leading to adrenal insufficiency. Symptoms include fatigue, weakness, nausea, vomiting, and hypotension. If adrenal insufficiency is diagnosed, treatment with corticosteroid replacement therapy may be necessary.
- Increased intracranial pressure: Fentanyl can elevate cerebrospinal fluid pressure. Use with extreme caution in patients with head injuries, brain tumors, or conditions that may increase intracranial pressure.
Pregnancy and Breastfeeding
Matrifen should not be used during pregnancy unless the potential benefit to the mother clearly justifies the potential risk to the fetus. Fentanyl crosses the placental barrier and may cause respiratory depression in the newborn. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated appropriately. Symptoms in the newborn include irritability, excessive crying, tremors, poor feeding, diarrhea, vomiting, and failure to gain weight. Women who require opioid therapy during pregnancy should be counseled about these risks and monitored closely.
Fentanyl is excreted in human breast milk and may cause sedation and respiratory depression in a breastfed infant. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue Matrifen, taking into account the importance of the drug to the mother. If Matrifen is discontinued, breastfeeding should not be resumed until at least 72 hours after the last patch removal, due to the prolonged elimination half-life of transdermal fentanyl.
Elderly Patients
Elderly patients (aged 65 years and older) may be more sensitive to the effects of fentanyl, particularly respiratory depression. This increased sensitivity may be due to age-related changes in pharmacokinetics (reduced hepatic metabolism, decreased renal clearance, altered body composition with increased fat stores) and pharmacodynamics (increased receptor sensitivity). Treatment should be initiated at the lowest available dose (12 mcg/h), with careful upward titration based on clinical response. Elderly patients should be monitored more frequently during initiation and dose adjustment.
Driving and Operating Machinery
Matrifen can impair mental and physical abilities required for potentially hazardous tasks such as driving a car or operating machinery. Patients should be warned about these effects, especially when initiating treatment, adjusting doses, or when Matrifen is combined with other CNS depressants. Do not drive or operate machinery until you know how Matrifen affects you. In many jurisdictions, driving while taking strong opioids may be subject to specific legal requirements; patients should consult local regulations.
How Does Matrifen Interact with Other Drugs?
Fentanyl is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4. Drugs that inhibit or induce this enzyme can significantly alter fentanyl plasma concentrations, with potentially dangerous clinical consequences. Additionally, the combined use of fentanyl with other central nervous system depressants or serotonergic agents creates additive or synergistic pharmacological effects that can be life-threatening.
Major Interactions
| Interacting Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Benzodiazepines (diazepam, lorazepam, alprazolam, midazolam) | Additive CNS depression | Profound sedation, respiratory depression, coma, death | Avoid combination. If essential, use lowest doses with close monitoring |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazodone) | Inhibition of fentanyl metabolism | Increased fentanyl plasma levels, prolonged opioid effects, fatal respiratory depression | Avoid if possible. If used, reduce fentanyl dose and monitor closely |
| Alcohol | Additive CNS depression | Enhanced sedation, respiratory depression, death | Strictly avoid alcohol during treatment |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline) | Enhanced serotonergic and opioid effects | Serotonin syndrome, severe hypertension, respiratory depression | Contraindicated within 14 days of MAO inhibitor use |
| Other opioids | Additive mu-opioid receptor activation | Increased risk of respiratory depression and overdose | Use breakthrough opioids cautiously with adjusted doses |
Other Notable Interactions
| Interacting Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St John’s Wort) | Increased fentanyl metabolism | Reduced fentanyl efficacy, breakthrough pain, possible withdrawal symptoms | Monitor for reduced efficacy; dose adjustment may be needed |
| SSRIs/SNRIs (sertraline, fluoxetine, venlafaxine, duloxetine) | Enhanced serotonergic activity | Serotonin syndrome risk (agitation, tremor, hyperthermia, rigidity) | Monitor for serotonin syndrome symptoms; use lowest effective doses |
| Gabapentinoids (gabapentin, pregabalin) | Additive CNS and respiratory depression | Increased risk of sedation, respiratory depression | Use caution; start with lower gabapentinoid doses |
| Mixed agonist-antagonists (buprenorphine, nalbuphine, pentazocine) | Partial agonist/antagonist at mu-receptor | Reduced fentanyl efficacy, possible withdrawal symptoms | Avoid combination |
| Muscle relaxants (baclofen, tizanidine, cyclobenzaprine) | Additive CNS depression | Enhanced sedation, respiratory depression | Use caution; monitor closely |
Grapefruit and grapefruit juice contain compounds that inhibit CYP3A4 and may increase fentanyl plasma levels. Patients using Matrifen should avoid consuming grapefruit or grapefruit juice in large quantities during treatment.
What Is the Correct Dosage of Matrifen?
Dosing of Matrifen must be individualized for each patient based on their current opioid regimen, pain severity, and overall clinical status. It is critical that prescribers have experience in managing patients with strong opioids and that they are familiar with equianalgesic dose conversion tables. The initial dose of Matrifen should be based on the patient’s 24-hour oral morphine equivalent dose (OMED), using published conversion ratios. Dose titration should be conservative, and patients should be closely monitored during the initial 72 hours of each new dose level.
Adults
| Oral Morphine (mg/24h) | Matrifen Patch Strength | Fentanyl Delivery Rate |
|---|---|---|
| 30–59 mg | Matrifen 12 mcg/h | 12 micrograms per hour |
| 60–89 mg | Matrifen 25 mcg/h | 25 micrograms per hour |
| 90–149 mg | Matrifen 50 mcg/h | 50 micrograms per hour |
| 150–209 mg | Matrifen 75 mcg/h | 75 micrograms per hour |
| 210–269 mg | Matrifen 100 mcg/h | 100 micrograms per hour |
When switching from oral or parenteral opioids to Matrifen, the previous opioid should be phased out gradually. For the first 12–24 hours after applying the first patch, the patient may require supplemental short-acting opioid analgesia, as therapeutic fentanyl levels take time to develop. After steady-state is reached (typically after the second patch application), the need for supplemental doses should decrease. Patients should always have access to a short-acting “rescue” opioid for breakthrough pain episodes.
Children and Adolescents
Matrifen should only be used in children aged 2 years and older who are already receiving opioid therapy equivalent to at least 30 mg oral morphine per day. The starting dose in children is calculated using the same equianalgesic conversion principles as for adults, beginning with the lowest appropriate patch strength. Children must be closely supervised by experienced healthcare professionals, and caregivers must be thoroughly educated about patch application, monitoring, and safe disposal. Matrifen patches must never be cut or divided, as this can damage the patch matrix and result in unpredictable and potentially dangerous drug release.
Elderly Patients
Elderly patients should be started on the lowest available dose (12 mcg/h) regardless of their current opioid dose, unless they are already receiving a higher equianalgesic fentanyl dose. Dose titration should be slower and more cautious in elderly patients. Pharmacokinetic studies have shown that elderly patients may have reduced fentanyl clearance by 20–30% compared with younger adults, resulting in higher plasma concentrations for a given dose. Close monitoring for signs of respiratory depression and excessive sedation is essential.
Missed or Delayed Patch Change
If you forget to change your patch at the scheduled time, apply a new patch as soon as you remember and note the new schedule. If the patch change is delayed by more than a few hours, there is a risk that plasma fentanyl levels may decline, leading to increased pain or withdrawal symptoms. Do not apply two patches to compensate for a missed change unless specifically instructed by your doctor. If the delay is significant (more than 12 hours), contact your healthcare provider for guidance.
Overdose
Signs of fentanyl overdose include extreme drowsiness, very slow or shallow breathing, cold and clammy skin, pinpoint pupils, loss of consciousness, and blue discoloration of lips and fingernails. A fentanyl overdose is a medical emergency. Call emergency services immediately. Remove the Matrifen patch and administer naloxone if available. Because fentanyl from a transdermal patch is released slowly and has a long duration of action, repeated doses of naloxone may be necessary, and the patient must be monitored for at least 24 hours after patch removal.
The management of fentanyl overdose centers on supportive care, establishment of a patent airway, assisted or controlled ventilation, and the use of naloxone (an opioid receptor antagonist). Naloxone has a shorter duration of action than fentanyl, so repeated doses or a continuous intravenous infusion may be required. Patients who have overdosed on transdermal fentanyl must be observed in a clinical setting for at least 24 hours after patch removal, as the subcutaneous depot can continue to release fentanyl into the circulation for many hours after the patch is removed.
What Are the Side Effects of Matrifen?
Like all opioid medications, Matrifen can cause side effects, although not everybody gets them. The side effects of fentanyl are typical of opioid agonist drugs, and most are dose-related. Many side effects are more pronounced during the initiation of therapy and may diminish with continued use as tolerance develops. However, constipation, a hallmark opioid side effect, typically persists throughout the duration of treatment and may require ongoing prophylactic management with laxatives.
The following side effects have been reported in clinical trials and post-marketing surveillance with transdermal fentanyl. They are classified by frequency according to the Medical Dictionary for Regulatory Activities (MedDRA) convention:
Very Common
Affects more than 1 in 10 patients
- Nausea
- Constipation
- Drowsiness (somnolence)
- Dizziness
- Headache
Common
Affects 1 in 10 to 1 in 100 patients
- Vomiting
- Diarrhea
- Dry mouth
- Abdominal pain
- Loss of appetite (anorexia)
- Fatigue
- Weakness (asthenia)
- Insomnia
- Anxiety
- Confusion
- Depression
- Tremor
- Itching (pruritus)
- Sweating (hyperhidrosis)
- Skin rash
- Application site reactions (redness, itching, rash)
- Urinary retention
- Peripheral edema
Uncommon
Affects 1 in 100 to 1 in 1,000 patients
- Respiratory depression
- Dyspnea (difficulty breathing)
- Hallucinations
- Euphoria
- Disorientation
- Memory impairment
- Muscle twitching (myoclonus)
- Palpitations
- Tachycardia
- Hypotension
- Blurred vision
- Sexual dysfunction
- Fever
Rare
Affects fewer than 1 in 1,000 patients
- Anaphylaxis
- Seizures
- Severe respiratory depression (potentially fatal)
- Apnea (cessation of breathing)
- Ileus (bowel obstruction)
- Bradycardia (slow heart rate)
- Severe hypotension
- Adrenal insufficiency
Not Known
Frequency cannot be estimated from available data
- Serotonin syndrome (when combined with serotonergic drugs)
- Neonatal opioid withdrawal syndrome (in newborns of mothers using fentanyl during pregnancy)
- Opioid use disorder (addiction, dependence)
- Withdrawal syndrome upon abrupt discontinuation
Contact emergency services immediately if you experience: very slow, shallow, or irregular breathing; extreme drowsiness or difficulty staying awake; cold, clammy skin; blue or purple discoloration of lips and fingernails; difficulty swallowing or breathing; severe dizziness or fainting; swelling of the face, lips, tongue, or throat (signs of anaphylaxis); or seizures. These may be signs of a life-threatening opioid overdose or severe allergic reaction.
Tolerance, Dependence, and Withdrawal
With prolonged use, physical dependence and tolerance to fentanyl will develop. Physical dependence means that abrupt discontinuation or rapid dose reduction will cause opioid withdrawal syndrome, characterized by restlessness, lacrimation (watery eyes), rhinorrhea (runny nose), yawning, sweating, chills, myalgia (muscle aches), dilated pupils, irritability, anxiety, insomnia, nausea, vomiting, diarrhea, abdominal cramps, and increased heart rate and blood pressure. Matrifen should never be stopped abruptly — the dose should be gradually reduced under medical supervision over days to weeks to minimize withdrawal symptoms.
Tolerance means that over time, higher doses may be needed to achieve the same level of pain relief. This is a normal physiological response and does not indicate addiction. However, fentanyl does carry a risk of opioid use disorder (addiction), which is characterized by compulsive drug use, craving, and continued use despite harm. Patients with a personal or family history of substance use disorders are at increased risk and should be monitored closely. The risk of developing opioid use disorder should be carefully weighed against the benefits of pain management for each individual patient.
How Should You Store Matrifen?
Proper storage of Matrifen patches is essential both for maintaining the medication’s effectiveness and for preventing potentially fatal accidental exposure. Fentanyl is an extremely potent substance, and even a used patch contains enough residual drug to cause serious harm or death in children, pets, or adults who are not opioid-tolerant.
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze. Keep the patches in their original sealed pouches until immediately before use to protect from moisture and light.
- Location: Store in a secure location, ideally in a locked cabinet or safe, out of the sight and reach of children, visitors, and pets. The small, translucent appearance of patches can make them easy for children to mistake for bandages or stickers.
- Do not use expired patches: Check the expiry date on the packaging. Do not use Matrifen after the expiry date. Return expired patches to a pharmacy for safe disposal.
- Handling: Do not open the sealed pouch until you are ready to apply the patch. If the patch is damaged, cut, or leaking, do not use it. Avoid touching the adhesive side of the patch. If accidental skin contact with the adhesive side occurs, wash the area thoroughly with water (do not use soap, alcohol, or other solvents, as they may enhance fentanyl absorption).
Disposal of Used Patches
Used Matrifen patches require careful disposal because they retain a significant amount of active fentanyl (often 50–80% of the original content). Improper disposal poses a serious risk, particularly to children and animals. Fold each used patch in half with the adhesive side inward so it sticks to itself. Place the folded patch back into its original pouch if available, or wrap it securely. Return used patches to your pharmacy for controlled disposal. Never throw patches in ordinary household waste, and never flush them unless specifically directed by your pharmacist or local waste guidelines. In healthcare settings, used patches should be disposed of in accordance with local controlled substance regulations.
What Does Matrifen Contain?
Matrifen is a matrix-type transdermal therapeutic system consisting of several layers designed to deliver fentanyl at a controlled rate through the skin. Understanding the composition of the patch helps explain how it works and why certain precautions (such as not cutting the patch) are important.
| Patch Designation | Release Rate | Total Fentanyl Content | Patch Size |
|---|---|---|---|
| Matrifen 12 mcg/h | 12.5 micrograms/hour | 2.1 mg | 5.25 cm² |
| Matrifen 25 mcg/h | 25 micrograms/hour | 4.2 mg | 10.5 cm² |
| Matrifen 50 mcg/h | 50 micrograms/hour | 8.4 mg | 21.0 cm² |
| Matrifen 75 mcg/h | 75 micrograms/hour | 12.6 mg | 31.5 cm² |
| Matrifen 100 mcg/h | 100 micrograms/hour | 16.8 mg | 42.0 cm² |
The Matrifen patch is a matrix-type transdermal system consisting of the following layers:
- Backing layer: An outer protective polyester film that is impermeable to fentanyl, preventing drug loss from the outer surface of the patch.
- Drug-containing matrix: A polyacrylate adhesive layer that contains the active substance (fentanyl) dispersed uniformly throughout the adhesive polymer. This matrix design means that the drug is distributed evenly across the entire patch area, rather than being contained in a separate reservoir. This is an important safety feature — if the patch is accidentally cut or damaged, the matrix design limits the risk of dose dumping that can occur with reservoir-type patches.
- Release liner: A protective peel-off layer that covers the adhesive surface before application. This liner is removed immediately before the patch is applied to the skin.
Excipients (inactive ingredients) include dipropylene glycol and a polyacrylate adhesive. The patch does not contain latex. Patients with known sensitivities to adhesive components should inform their healthcare provider, as skin reactions at the application site are among the most common side effects.
How Do You Apply and Use the Matrifen Patch?
Proper application of the Matrifen patch is essential for safe and effective pain management. Incorrect application can result in inadequate drug delivery (poor adhesion) or, conversely, excessive absorption (if applied to damaged skin or exposed to heat). Follow these step-by-step instructions carefully:
Step 1: Choose the Application Site
Select a flat, clean area of skin on the upper chest, upper back, upper arm, or upper thigh. The skin must be non-hairy (shave if necessary, but do not shave immediately before application as this may irritate the skin), non-irritated, non-irradiated, and free from cuts, rashes, or other skin conditions. Avoid areas with excessive body movement. Rotate the application site with each new patch — do not use the same site for consecutive patches. Wait at least 7 days before reusing a site.
Step 2: Prepare the Skin
If the skin needs cleaning, use only water. Do not use soap, oils, lotions, alcohol, or other agents that could alter the skin barrier and affect drug absorption. Allow the skin to dry completely before applying the patch. If hair needs to be removed from the site, use scissors to clip the hair close to the skin — do not use a razor.
Step 3: Apply the Patch
Open the sealed pouch by tearing along the notch (do not use scissors, as you might accidentally damage the patch). Remove the patch and peel off the protective release liner. Immediately press the patch firmly onto the chosen skin site with the palm of your hand for at least 30 seconds, making sure the edges are sealed and that there is complete contact between the patch and the skin. If the edges of the patch lift, secure them with medical adhesive tape. Do not use household tape.
Step 4: Wear and Monitor
Wear each patch continuously for 72 hours (3 days). You can shower or bathe while wearing the patch (avoid very hot water), but avoid prolonged soaking. If the patch falls off before 72 hours, fold it and dispose of it safely, then apply a new patch to a different site. Note the new schedule. If the patch falls off repeatedly, consult your pharmacist about waterproof adhesive dressings designed for transdermal patches.
Step 5: Replace the Patch
After 72 hours, remove the old patch by gently peeling it off. Fold it in half with the adhesive sides together. Apply a new patch to a different skin site. Wash your hands after handling patches. Dispose of the used patch safely by returning it to a pharmacy.
Never cut or divide the patch. Cutting the patch can damage the drug matrix and lead to uncontrolled, rapid release of fentanyl. Never apply a damaged or leaking patch. Wash hands with plain water after application (soap is not necessary and should not be used on the patch site). If fentanyl gel accidentally contacts the skin, wash the area with water only.
Frequently Asked Questions About Matrifen
Matrifen is a transdermal fentanyl patch used for the management of chronic severe pain that requires continuous, around-the-clock opioid treatment and cannot be adequately managed by other pain medications. It is commonly prescribed for cancer pain and severe non-cancer chronic pain in patients who are already opioid-tolerant. Matrifen is NOT suitable for acute, intermittent, or postoperative pain, and must only be used in patients already receiving regular opioid therapy.
Apply the Matrifen patch to a flat, non-irritated, non-irradiated area of skin on the upper body (chest, back, upper arm) or upper thigh. Clean the area with water only (no soap, oils, or lotions). Press the patch firmly with the palm of your hand for at least 30 seconds, ensuring complete contact especially at the edges. Each patch is worn for 72 hours (3 days), then replaced with a new patch on a different skin site. Avoid exposing the patch to direct heat sources such as heating pads, saunas, or hot baths.
The most dangerous side effect of Matrifen is respiratory depression (slowed or stopped breathing), which can be fatal. This risk is highest when starting treatment, after dose increases, and when combined with other CNS depressants such as benzodiazepines or alcohol. Other serious risks include severe hypotension, serotonin syndrome, adrenal insufficiency, and the potential for opioid use disorder (addiction). Accidental exposure in children or non-opioid-tolerant individuals can cause fatal overdose.
No. Matrifen must NOT be used in opioid-naive patients (people who have not previously been taking regular opioid medications). The fentanyl doses delivered even by the lowest-strength patch (12 mcg/h) can cause fatal respiratory depression in individuals who are not tolerant to opioid effects. Patients must already be receiving and tolerant to at least 60 mg oral morphine equivalents per day (or equivalent dose of another opioid for at least one week) before starting Matrifen.
External heat sources such as heating pads, electric blankets, saunas, hot baths, sunbathing, and fever can increase the rate at which fentanyl is absorbed through the skin by dilating blood vessels and increasing skin permeability. Studies have shown that heat exposure can increase fentanyl absorption by up to 120%. This can lead to dangerously high blood levels of fentanyl, potentially causing fatal respiratory depression and overdose. Patients wearing Matrifen patches should avoid direct heat exposure to the patch site and should be monitored closely during febrile illness.
Used Matrifen patches still contain significant amounts of fentanyl (often 50–80% of the original content) and must be disposed of safely. Fold the used patch in half with the adhesive sides together so they stick to each other, then return it to the pharmacy for safe, controlled disposal. Never throw used patches in household waste or flush them down the toilet unless specifically instructed. Keep all patches, both new and used, out of the reach of children and pets, as accidental exposure can be fatal. In healthcare settings, used patches must be disposed of according to controlled substance regulations.
References
- European Medicines Agency (EMA). Matrifen — Summary of Product Characteristics. Last updated 2024. Available from: EMA product information database.
- U.S. Food and Drug Administration (FDA). Fentanyl Transdermal System — Prescribing Information. Revised 2024.
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018.
- Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2024;35(11):920–938.
- Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev. 2013;(10):CD010270. doi:10.1002/14651858.CD010270.pub2.
- Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008;11(3):492–501.
- British National Formulary (BNF). Fentanyl — Transdermal route. NICE Evidence Services. Accessed December 2025.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–632.
- Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5(4):230–241.
Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in Pain Medicine, Palliative Care, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent panel of physicians who verify accuracy against international guidelines
Evidence Framework
GRADE methodology — WHO, EMA, FDA, ESMO, BNF, and CDC guidelines
Last Review
This article was last medically reviewed on and is scheduled for review within 6 months
All medical content on iMedic is created by qualified medical professionals and reviewed according to the iMedic Editorial Standards. Our content is independent, evidence-based, and free from commercial influence.